Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study

Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment. 59 patients...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-08, Vol.7 (31), p.50656-50665
Main Authors: Li, Qian, Jiang, Huiqin, Li, Hong, Xu, Ruihua, Shen, Lin, Yu, Yiyi, Wang, Yan, Cui, Yuehong, Li, Wei, Yu, Shan, Liu, Tianshu
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Clinical Research Paper
Disease Progression
Disease-Free Survival
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Prognosis
Prospective Studies
Receptor, ErbB-2 - metabolism
Stomach Neoplasms - drug therapy
Stomach Neoplasms - metabolism
Trastuzumab - administration & dosage
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment. 59 patients were enrolled from Zhongshan Hospital Fudan University, Sun Yat-sen University Cancer Center and Peking University Cancer Hospital between September 2012 and Oct 2015. Patients were divided into two groups according to the second line regimens: with or without trastuzumab. The primary endpoint was progression free survival of second line therapy (PFS2). Secondary end points included overall survival (OS), response rate, and adverse events (AEs). Baseline factors were well balanced between two groups. 32 patients treated with trastuzumab plus second line chemotherapy (group A) and 27 patients received chemotherapy alone (group B). The median follow-up time was 7.60 months (range 1.50-32.50). Longer median PFS2 was observed in group A than in group B (3.1 vs 2.0 months, P=0.008). There was no significant differences of median OS2 calculating from the second line therapy (10.5 vs 6.5 months, P=0.172) between two groups. Response rate was 9.3% in group A compared with 3.7% in group B (P=0.617). AEs were similar in two groups including cardiac safety. Subgroup analysis showed that factors of male, age
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.10456